Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASCO In Brief

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Velcade sNDA perches on a PINNACLE: Mantle cell lymphoma (MCL) could be the next indication for Millennium/J&J's Velcade (bortezomib), based on data from the PINNACLE study of relapsed or refractory patients with MCL, an aggressive subtype of non-Hodgkin's lymphoma. The firms announced the submission of an sNDA for treatment of relapsed or refractory MCL June 9. Millennium presented the pivotal Phase II PINNACLE trial at the American Society of Clinical Oncology meeting in Atlanta June 2-6. The single-arm trial enrolled 155 patients treated with at least two prior therapies. Patients received Velcade alone twice weekly for two weeks every 21 days for up to one year. Velcade patients demonstrated a 33% response rate and an 8% complete response rate; the median duration of response was 9.2 months, and 13.5 months in patients achieving a complete response. On the primary endpoint of time to progression, patients with a complete response had a median TTP of 19.3 months; median TTP overall was 6.2 months...

You may also be interested in...

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals


Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care

The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts